Brought to you by 
United Therapeutics to acquire SteadyMed
03 Sep 2020
Executive Summary
United Therapeutics Corp. is paying $4.46 per share in cash (a 55% premium) to acquire SteadyMed Ltd. United Therapeutics will also shell out $2.63 per share in cash based on a commercialization milestone for Trevyent. The deal is valued at $216mm, which includes $75mm in contingent payments.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Macromolecule
- Transdermal
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
United Therapeutics to acquire SteadyMed
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice